Company intelligence / Profile preview

Theragnostics

Ownership: Private
Development stage: Commercial

Overview

Theragnostics developed a pipeline of radio-labeled PARP inhibitors for both cancer diagnosis and treatment. Its lead diagnostic asset, THG‑008, is in Phase I trials at Memorial Sloan Kettering Hospital. The company also developed THG‑009 as a therapeutic candidate targeting glioblastoma. NEPHROSCAN™, an FDA-approved kidney imaging agent co-developed with GE Healthcare, is commercially available in the US. The company’s Ga‑68 kit technology is licensed to Novartis.

Therapeutic areas: OncologyNephrology
Modalities: Radiolabeled small molecules (PARP inhibitors)Diagnostic radiopharmaceuticals
Industry: Biotech

Drug pipeline

1 asset

technetium tc 99m succimer

Approved

Partnerships

GE Healthcare – partnership on NEPHROSCAN™ development/commercialization.Novartis – licensee of Ga–68 kit technology IP.

Beyond the preview

Go deeper on Theragnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theragnostics.

Explore the full profile